| Followers | 46 |
| Posts | 3530 |
| Boards Moderated | 1 |
| Alias Born | 01/18/2016 |
Tuesday, January 21, 2025 8:53:21 PM
Coya announces the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory diseases.
https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/95283171/coya-therapeutics-announces-pipeline-expansion-c
https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/95283171/coya-therapeutics-announces-pipeline-expansion-c
All my postings are verified and approved by my dog.
Recent COYA News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:48:35 PM
- Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director • Business Wire • 04/02/2026 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/23/2026 04:15:19 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/20/2026 08:30:27 PM
- Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy • Business Wire • 03/18/2026 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/16/2026 01:20:37 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/16/2026 12:11:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 12:07:44 PM
- Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results • Business Wire • 03/16/2026 12:00:00 PM
- Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial • Business Wire • 02/10/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2026 01:06:48 PM
- Coya Therapeutics Announces $11.1 Million Private Placement • Business Wire • 01/30/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2026 01:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2026 01:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 01:20:20 PM
- Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders • Business Wire • 01/20/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 01:10:31 PM
- Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients • Business Wire • 01/08/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 12:21:56 AM
- Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) • Business Wire • 01/05/2026 01:00:00 PM
- Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) • Business Wire • 12/23/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/17/2025 01:00:15 PM
- Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS • Business Wire • 12/09/2025 01:00:00 PM
- Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences • Business Wire • 11/25/2025 01:00:00 PM
